OnCore Login

Return to Trial Database

GU03-67

A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67

Status

Study Completed

Cancer Type(s)

Prostate

Study Contact

Publications

A Multicenter Phase II Study of Pemetrexed for the Treatment of Hormone Refractory Prostate Cancer (HRPC) with Reduced Folate Carrier 1 (RFC1) Pharmacogenetic Analysis
  • NM Hahn, F Ademuyiwa, RT Zon, T Jones, W Dugan, C Whalen, M Yu, R Shanmugam, T Skaar, CJ Sweeney
Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC)
  • NM Hahn, C Whalen, CJ Sweeney
A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC)
  • NM Hahn, RT Zon, M Yu, FO Ademuyiwa, T Jones, W Dugan, C Whalen, R Shanmugam, T Skaar, CJ Sweeney

Trial Locations

All sites in which the trial GU03-67 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278